nodes	percent_of_prediction	percent_of_DWPC	metapath
Naphazoline—ADRA2A—type 2 diabetes mellitus	0.43	1	CbGaD
Naphazoline—ADRA2C—Bromocriptine—type 2 diabetes mellitus	0.115	0.309	CbGbCtD
Naphazoline—ADRA2B—Bromocriptine—type 2 diabetes mellitus	0.109	0.293	CbGbCtD
Naphazoline—ADRA2A—Bromocriptine—type 2 diabetes mellitus	0.0759	0.204	CbGbCtD
Naphazoline—ADRA1A—Bromocriptine—type 2 diabetes mellitus	0.0727	0.195	CbGbCtD
Naphazoline—Ocular discomfort—Bromocriptine—type 2 diabetes mellitus	0.00662	0.0664	CcSEcCtD
Naphazoline—Sweating—Nateglinide—type 2 diabetes mellitus	0.00134	0.0134	CcSEcCtD
Naphazoline—Erythema—Tolbutamide—type 2 diabetes mellitus	0.00129	0.013	CcSEcCtD
Naphazoline—Hyperglycaemia—Repaglinide—type 2 diabetes mellitus	0.00122	0.0122	CcSEcCtD
Naphazoline—Erythema—Tolazamide—type 2 diabetes mellitus	0.00118	0.0118	CcSEcCtD
Naphazoline—Hyperglycaemia—Rosiglitazone—type 2 diabetes mellitus	0.00115	0.0116	CcSEcCtD
Naphazoline—Terbinafine—CYP11A1—type 2 diabetes mellitus	0.00115	0.253	CrCbGaD
Naphazoline—Erythema—Acarbose—type 2 diabetes mellitus	0.00113	0.0113	CcSEcCtD
Naphazoline—Eye disorder—Repaglinide—type 2 diabetes mellitus	0.00101	0.0102	CcSEcCtD
Naphazoline—Drowsiness—Glipizide—type 2 diabetes mellitus	0.000998	0.01	CcSEcCtD
Naphazoline—Discomfort—Tolazamide—type 2 diabetes mellitus	0.000989	0.00992	CcSEcCtD
Naphazoline—Hyperglycaemia—Pioglitazone—type 2 diabetes mellitus	0.000968	0.00971	CcSEcCtD
Naphazoline—Sweating—Glipizide—type 2 diabetes mellitus	0.000957	0.0096	CcSEcCtD
Naphazoline—Eye disorder—Rosiglitazone—type 2 diabetes mellitus	0.000957	0.0096	CcSEcCtD
Naphazoline—Erythema—Repaglinide—type 2 diabetes mellitus	0.000943	0.00946	CcSEcCtD
Naphazoline—Hyperglycaemia—Sitagliptin—type 2 diabetes mellitus	0.00094	0.00943	CcSEcCtD
Naphazoline—NISCH—islet of Langerhans—type 2 diabetes mellitus	0.000938	0.111	CbGeAlD
Naphazoline—Drowsiness—Glimepiride—type 2 diabetes mellitus	0.000932	0.00935	CcSEcCtD
Naphazoline—Sweating—Pioglitazone—type 2 diabetes mellitus	0.000917	0.0092	CcSEcCtD
Naphazoline—ADRA2A—peripheral nervous system—type 2 diabetes mellitus	0.000906	0.107	CbGeAlD
Naphazoline—Sweating—Glimepiride—type 2 diabetes mellitus	0.000893	0.00896	CcSEcCtD
Naphazoline—Hyperhidrosis—Nateglinide—type 2 diabetes mellitus	0.00086	0.00862	CcSEcCtD
Naphazoline—Drowsiness—Bromocriptine—type 2 diabetes mellitus	0.000841	0.00843	CcSEcCtD
Naphazoline—Eye disorder—Glipizide—type 2 diabetes mellitus	0.000838	0.0084	CcSEcCtD
Naphazoline—Hypertension—Repaglinide—type 2 diabetes mellitus	0.000814	0.00817	CcSEcCtD
Naphazoline—Eye disorder—Pioglitazone—type 2 diabetes mellitus	0.000802	0.00805	CcSEcCtD
Naphazoline—Erythema—Glipizide—type 2 diabetes mellitus	0.00078	0.00783	CcSEcCtD
Naphazoline—Eye disorder—Sitagliptin—type 2 diabetes mellitus	0.000779	0.00782	CcSEcCtD
Naphazoline—Hypertension—Rosiglitazone—type 2 diabetes mellitus	0.00077	0.00772	CcSEcCtD
Naphazoline—Tension—Glipizide—type 2 diabetes mellitus	0.000766	0.00768	CcSEcCtD
Naphazoline—Nervousness—Glipizide—type 2 diabetes mellitus	0.000758	0.0076	CcSEcCtD
Naphazoline—NISCH—nephron tubule—type 2 diabetes mellitus	0.000756	0.089	CbGeAlD
Naphazoline—Phentolamine—ADRA2A—type 2 diabetes mellitus	0.000743	0.164	CrCbGaD
Naphazoline—Vision blurred—Glipizide—type 2 diabetes mellitus	0.000735	0.00738	CcSEcCtD
Naphazoline—Erythema—Glimepiride—type 2 diabetes mellitus	0.000728	0.0073	CcSEcCtD
Naphazoline—Tension—Glimepiride—type 2 diabetes mellitus	0.000715	0.00717	CcSEcCtD
Naphazoline—Tension—Sitagliptin—type 2 diabetes mellitus	0.000712	0.00714	CcSEcCtD
Naphazoline—Nervousness—Glimepiride—type 2 diabetes mellitus	0.000707	0.00709	CcSEcCtD
Naphazoline—Eye disorder—Bromocriptine—type 2 diabetes mellitus	0.000705	0.00707	CcSEcCtD
Naphazoline—Nervousness—Sitagliptin—type 2 diabetes mellitus	0.000705	0.00707	CcSEcCtD
Naphazoline—Hyperglycaemia—Gliclazide—type 2 diabetes mellitus	0.000698	0.007	CcSEcCtD
Naphazoline—Nausea—Miglitol—type 2 diabetes mellitus	0.000697	0.00699	CcSEcCtD
Naphazoline—Drowsiness—Gliclazide—type 2 diabetes mellitus	0.00069	0.00692	CcSEcCtD
Naphazoline—Asthenia—Tolazamide—type 2 diabetes mellitus	0.000689	0.00691	CcSEcCtD
Naphazoline—Vision blurred—Glimepiride—type 2 diabetes mellitus	0.000686	0.00688	CcSEcCtD
Naphazoline—Vision blurred—Sitagliptin—type 2 diabetes mellitus	0.000684	0.00686	CcSEcCtD
Naphazoline—Hypertension—Glipizide—type 2 diabetes mellitus	0.000674	0.00676	CcSEcCtD
Naphazoline—Sweating—Gliclazide—type 2 diabetes mellitus	0.000661	0.00663	CcSEcCtD
Naphazoline—Headache—Tolbutamide—type 2 diabetes mellitus	0.000661	0.00663	CcSEcCtD
Naphazoline—NISCH—pancreas—type 2 diabetes mellitus	0.00066	0.0777	CbGeAlD
Naphazoline—Discomfort—Glipizide—type 2 diabetes mellitus	0.000656	0.00658	CcSEcCtD
Naphazoline—NISCH—cortex of kidney—type 2 diabetes mellitus	0.000647	0.0762	CbGeAlD
Naphazoline—Hypertension—Pioglitazone—type 2 diabetes mellitus	0.000645	0.00647	CcSEcCtD
Naphazoline—Eye disorder—Glyburide—type 2 diabetes mellitus	0.000645	0.00647	CcSEcCtD
Naphazoline—Tension—Bromocriptine—type 2 diabetes mellitus	0.000645	0.00647	CcSEcCtD
Naphazoline—Asthenia—Nateglinide—type 2 diabetes mellitus	0.000638	0.0064	CcSEcCtD
Naphazoline—Nervousness—Bromocriptine—type 2 diabetes mellitus	0.000638	0.0064	CcSEcCtD
Naphazoline—Dizziness—Tolazamide—type 2 diabetes mellitus	0.000635	0.00637	CcSEcCtD
Naphazoline—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.000635	0.00637	CcSEcCtD
Naphazoline—Discomfort—Pioglitazone—type 2 diabetes mellitus	0.000629	0.00631	CcSEcCtD
Naphazoline—Hypertension—Glimepiride—type 2 diabetes mellitus	0.000629	0.00631	CcSEcCtD
Naphazoline—Nausea—Tolbutamide—type 2 diabetes mellitus	0.000627	0.00629	CcSEcCtD
Naphazoline—Hypertension—Sitagliptin—type 2 diabetes mellitus	0.000627	0.00629	CcSEcCtD
Naphazoline—Vision blurred—Bromocriptine—type 2 diabetes mellitus	0.000619	0.00621	CcSEcCtD
Naphazoline—Hyperhidrosis—Glipizide—type 2 diabetes mellitus	0.000616	0.00617	CcSEcCtD
Naphazoline—Discomfort—Sitagliptin—type 2 diabetes mellitus	0.000611	0.00612	CcSEcCtD
Naphazoline—Headache—Chlorpropamide—type 2 diabetes mellitus	0.000601	0.00603	CcSEcCtD
Naphazoline—Headache—Tolazamide—type 2 diabetes mellitus	0.000601	0.00603	CcSEcCtD
Naphazoline—Erythema—Glyburide—type 2 diabetes mellitus	0.0006	0.00602	CcSEcCtD
Naphazoline—NISCH—adipose tissue—type 2 diabetes mellitus	0.000598	0.0705	CbGeAlD
Naphazoline—Headache—Linagliptin—type 2 diabetes mellitus	0.000595	0.00597	CcSEcCtD
Naphazoline—Hyperhidrosis—Pioglitazone—type 2 diabetes mellitus	0.00059	0.00592	CcSEcCtD
Naphazoline—Dizziness—Nateglinide—type 2 diabetes mellitus	0.000588	0.0059	CcSEcCtD
Naphazoline—Eye disorder—Gliclazide—type 2 diabetes mellitus	0.000579	0.00581	CcSEcCtD
Naphazoline—Drowsiness—Metformin—type 2 diabetes mellitus	0.000577	0.00579	CcSEcCtD
Naphazoline—Hyperhidrosis—Glimepiride—type 2 diabetes mellitus	0.000574	0.00576	CcSEcCtD
Naphazoline—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00057	0.00572	CcSEcCtD
Naphazoline—Nausea—Tolazamide—type 2 diabetes mellitus	0.00057	0.00572	CcSEcCtD
Naphazoline—Hypertension—Bromocriptine—type 2 diabetes mellitus	0.000567	0.00569	CcSEcCtD
Naphazoline—Somnolence—Glipizide—type 2 diabetes mellitus	0.000566	0.00568	CcSEcCtD
Naphazoline—Vision blurred—Glyburide—type 2 diabetes mellitus	0.000566	0.00568	CcSEcCtD
Naphazoline—Hyperglycaemia—Irbesartan—type 2 diabetes mellitus	0.000551	0.00553	CcSEcCtD
Naphazoline—Nausea—Acarbose—type 2 diabetes mellitus	0.000548	0.00549	CcSEcCtD
Naphazoline—Erythema—Gliclazide—type 2 diabetes mellitus	0.000539	0.00541	CcSEcCtD
Naphazoline—Tension—Gliclazide—type 2 diabetes mellitus	0.000529	0.00531	CcSEcCtD
Naphazoline—Somnolence—Glimepiride—type 2 diabetes mellitus	0.000528	0.0053	CcSEcCtD
Naphazoline—Nausea—Nateglinide—type 2 diabetes mellitus	0.000528	0.0053	CcSEcCtD
Naphazoline—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000527	0.00528	CcSEcCtD
Naphazoline—Nervousness—Gliclazide—type 2 diabetes mellitus	0.000524	0.00525	CcSEcCtD
Naphazoline—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.000522	0.00523	CcSEcCtD
Naphazoline—Hyperglycaemia—Losartan—type 2 diabetes mellitus	0.000519	0.0052	CcSEcCtD
Naphazoline—Propranolol—ADRB3—type 2 diabetes mellitus	0.000502	0.111	CrCbGaD
Naphazoline—Sweating—Losartan—type 2 diabetes mellitus	0.000492	0.00493	CcSEcCtD
Naphazoline—Eye disorder—Metformin—type 2 diabetes mellitus	0.000484	0.00486	CcSEcCtD
Naphazoline—Headache—Repaglinide—type 2 diabetes mellitus	0.000482	0.00484	CcSEcCtD
Naphazoline—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000481	0.00482	CcSEcCtD
Naphazoline—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000477	0.00478	CcSEcCtD
Naphazoline—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000474	0.00475	CcSEcCtD
Naphazoline—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000467	0.00468	CcSEcCtD
Naphazoline—Hypertension—Gliclazide—type 2 diabetes mellitus	0.000466	0.00467	CcSEcCtD
Naphazoline—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000461	0.00463	CcSEcCtD
Naphazoline—Nausea—Repaglinide—type 2 diabetes mellitus	0.000457	0.00459	CcSEcCtD
Naphazoline—Asthenia—Glipizide—type 2 diabetes mellitus	0.000457	0.00458	CcSEcCtD
Naphazoline—Headache—Rosiglitazone—type 2 diabetes mellitus	0.000456	0.00457	CcSEcCtD
Naphazoline—Discomfort—Gliclazide—type 2 diabetes mellitus	0.000454	0.00455	CcSEcCtD
Naphazoline—Erythema—Metformin—type 2 diabetes mellitus	0.000451	0.00452	CcSEcCtD
Naphazoline—Tolazoline—ADRA2A—type 2 diabetes mellitus	0.000438	0.0967	CrCbGaD
Naphazoline—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000438	0.00439	CcSEcCtD
Naphazoline—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000432	0.00433	CcSEcCtD
Naphazoline—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000426	0.00428	CcSEcCtD
Naphazoline—Erythema—Irbesartan—type 2 diabetes mellitus	0.000426	0.00427	CcSEcCtD
Naphazoline—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000425	0.00427	CcSEcCtD
Naphazoline—Vision blurred—Metformin—type 2 diabetes mellitus	0.000425	0.00426	CcSEcCtD
Naphazoline—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000425	0.00426	CcSEcCtD
Naphazoline—Sweating—Ramipril—type 2 diabetes mellitus	0.000421	0.00423	CcSEcCtD
Naphazoline—Dizziness—Glipizide—type 2 diabetes mellitus	0.000421	0.00422	CcSEcCtD
Naphazoline—Terbinafine—CYP1A2—type 2 diabetes mellitus	0.000421	0.0929	CrCbGaD
Naphazoline—Duloxetine—HTR2C—type 2 diabetes mellitus	0.000421	0.0928	CrCbGaD
Naphazoline—NISCH—liver—type 2 diabetes mellitus	0.00042	0.0495	CbGeAlD
Naphazoline—Tension—Irbesartan—type 2 diabetes mellitus	0.000418	0.00419	CcSEcCtD
Naphazoline—Nervousness—Irbesartan—type 2 diabetes mellitus	0.000414	0.00415	CcSEcCtD
Naphazoline—Discomfort—Orlistat—type 2 diabetes mellitus	0.000412	0.00413	CcSEcCtD
Naphazoline—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000403	0.00405	CcSEcCtD
Naphazoline—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000401	0.00402	CcSEcCtD
Naphazoline—Erythema—Losartan—type 2 diabetes mellitus	0.000401	0.00402	CcSEcCtD
Naphazoline—Headache—Glipizide—type 2 diabetes mellitus	0.000399	0.004	CcSEcCtD
Naphazoline—Tension—Losartan—type 2 diabetes mellitus	0.000393	0.00394	CcSEcCtD
Naphazoline—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000393	0.00394	CcSEcCtD
Naphazoline—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000392	0.00393	CcSEcCtD
Naphazoline—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000391	0.00392	CcSEcCtD
Naphazoline—Hypertension—Metformin—type 2 diabetes mellitus	0.000389	0.00391	CcSEcCtD
Naphazoline—Nervousness—Losartan—type 2 diabetes mellitus	0.000389	0.0039	CcSEcCtD
Naphazoline—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000386	0.00387	CcSEcCtD
Naphazoline—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000385	0.00386	CcSEcCtD
Naphazoline—Headache—Pioglitazone—type 2 diabetes mellitus	0.000382	0.00383	CcSEcCtD
Naphazoline—Discomfort—Metformin—type 2 diabetes mellitus	0.000379	0.00381	CcSEcCtD
Naphazoline—Nausea—Glipizide—type 2 diabetes mellitus	0.000378	0.00379	CcSEcCtD
Naphazoline—Vision blurred—Losartan—type 2 diabetes mellitus	0.000378	0.00379	CcSEcCtD
Naphazoline—Headache—Glimepiride—type 2 diabetes mellitus	0.000372	0.00373	CcSEcCtD
Naphazoline—Headache—Sitagliptin—type 2 diabetes mellitus	0.000371	0.00372	CcSEcCtD
Naphazoline—Hypertension—Irbesartan—type 2 diabetes mellitus	0.000368	0.00369	CcSEcCtD
Naphazoline—Somnolence—Valsartan—type 2 diabetes mellitus	0.000359	0.00361	CcSEcCtD
Naphazoline—Discomfort—Irbesartan—type 2 diabetes mellitus	0.000358	0.00359	CcSEcCtD
Naphazoline—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000356	0.00357	CcSEcCtD
Naphazoline—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000355	0.00356	CcSEcCtD
Naphazoline—Nausea—Glimepiride—type 2 diabetes mellitus	0.000353	0.00354	CcSEcCtD
Naphazoline—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000352	0.00353	CcSEcCtD
Naphazoline—Asthenia—Glyburide—type 2 diabetes mellitus	0.000352	0.00353	CcSEcCtD
Naphazoline—ADRA2C—nephron tubule—type 2 diabetes mellitus	0.000345	0.0407	CbGeAlD
Naphazoline—Erythema—Ramipril—type 2 diabetes mellitus	0.000344	0.00345	CcSEcCtD
Naphazoline—ADRA2A—islet of Langerhans—type 2 diabetes mellitus	0.000342	0.0403	CbGeAlD
Naphazoline—Tension—Ramipril—type 2 diabetes mellitus	0.000337	0.00338	CcSEcCtD
Naphazoline—Discomfort—Losartan—type 2 diabetes mellitus	0.000337	0.00338	CcSEcCtD
Naphazoline—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000336	0.00337	CcSEcCtD
Naphazoline—Headache—Bromocriptine—type 2 diabetes mellitus	0.000336	0.00337	CcSEcCtD
Naphazoline—Nervousness—Ramipril—type 2 diabetes mellitus	0.000334	0.00335	CcSEcCtD
Naphazoline—Somnolence—Metformin—type 2 diabetes mellitus	0.000327	0.00328	CcSEcCtD
Naphazoline—ADRA1A—cardiovascular system—type 2 diabetes mellitus	0.000325	0.0383	CbGeAlD
Naphazoline—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000318	0.00319	CcSEcCtD
Naphazoline—Duloxetine—CYP1A2—type 2 diabetes mellitus	0.000317	0.0701	CrCbGaD
Naphazoline—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000316	0.00317	CcSEcCtD
Naphazoline—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000316	0.00317	CcSEcCtD
Naphazoline—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000309	0.0031	CcSEcCtD
Naphazoline—Headache—Glyburide—type 2 diabetes mellitus	0.000307	0.00308	CcSEcCtD
Naphazoline—ADRA2C—kidney—type 2 diabetes mellitus	0.000303	0.0357	CbGeAlD
Naphazoline—ADRA2C—pancreas—type 2 diabetes mellitus	0.000301	0.0355	CbGeAlD
Naphazoline—ADRA2C—cortex of kidney—type 2 diabetes mellitus	0.000295	0.0348	CbGeAlD
Naphazoline—Nausea—Glyburide—type 2 diabetes mellitus	0.000291	0.00292	CcSEcCtD
Naphazoline—Dizziness—Gliclazide—type 2 diabetes mellitus	0.000291	0.00292	CcSEcCtD
Naphazoline—Somnolence—Losartan—type 2 diabetes mellitus	0.000291	0.00292	CcSEcCtD
Naphazoline—Asthenia—Valsartan—type 2 diabetes mellitus	0.00029	0.00291	CcSEcCtD
Naphazoline—Discomfort—Ramipril—type 2 diabetes mellitus	0.000289	0.0029	CcSEcCtD
Naphazoline—ADRA1A—adipose tissue—type 2 diabetes mellitus	0.000287	0.0338	CbGeAlD
Naphazoline—Asthenia—Orlistat—type 2 diabetes mellitus	0.000287	0.00288	CcSEcCtD
Naphazoline—Terbinafine—CYP3A4—type 2 diabetes mellitus	0.000279	0.0615	CrCbGaD
Naphazoline—Headache—Gliclazide—type 2 diabetes mellitus	0.000276	0.00277	CcSEcCtD
Naphazoline—ADRA2C—adipose tissue—type 2 diabetes mellitus	0.000273	0.0322	CbGeAlD
Naphazoline—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000271	0.00272	CcSEcCtD
Naphazoline—Dizziness—Valsartan—type 2 diabetes mellitus	0.000267	0.00268	CcSEcCtD
Naphazoline—Dizziness—Orlistat—type 2 diabetes mellitus	0.000264	0.00265	CcSEcCtD
Naphazoline—Asthenia—Metformin—type 2 diabetes mellitus	0.000264	0.00265	CcSEcCtD
Naphazoline—Nausea—Gliclazide—type 2 diabetes mellitus	0.000261	0.00262	CcSEcCtD
Naphazoline—Headache—Valsartan—type 2 diabetes mellitus	0.000253	0.00254	CcSEcCtD
Naphazoline—Headache—Orlistat—type 2 diabetes mellitus	0.00025	0.00251	CcSEcCtD
Naphazoline—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000249	0.0025	CcSEcCtD
Naphazoline—Somnolence—Ramipril—type 2 diabetes mellitus	0.000249	0.0025	CcSEcCtD
Naphazoline—Dizziness—Metformin—type 2 diabetes mellitus	0.000243	0.00244	CcSEcCtD
Naphazoline—ADRA2A—pancreas—type 2 diabetes mellitus	0.00024	0.0283	CbGeAlD
Naphazoline—Nausea—Valsartan—type 2 diabetes mellitus	0.00024	0.00241	CcSEcCtD
Naphazoline—Nausea—Orlistat—type 2 diabetes mellitus	0.000237	0.00238	CcSEcCtD
Naphazoline—ADRA2A—cortex of kidney—type 2 diabetes mellitus	0.000236	0.0278	CbGeAlD
Naphazoline—Asthenia—Losartan—type 2 diabetes mellitus	0.000235	0.00235	CcSEcCtD
Naphazoline—Headache—Metformin—type 2 diabetes mellitus	0.000231	0.00231	CcSEcCtD
Naphazoline—Dizziness—Irbesartan—type 2 diabetes mellitus	0.00023	0.0023	CcSEcCtD
Naphazoline—Nausea—Metformin—type 2 diabetes mellitus	0.000219	0.00219	CcSEcCtD
Naphazoline—ADRA2A—adipose tissue—type 2 diabetes mellitus	0.000218	0.0257	CbGeAlD
Naphazoline—Headache—Irbesartan—type 2 diabetes mellitus	0.000218	0.00218	CcSEcCtD
Naphazoline—Dizziness—Losartan—type 2 diabetes mellitus	0.000216	0.00217	CcSEcCtD
Naphazoline—Nausea—Irbesartan—type 2 diabetes mellitus	0.000206	0.00207	CcSEcCtD
Naphazoline—Headache—Losartan—type 2 diabetes mellitus	0.000205	0.00205	CcSEcCtD
Naphazoline—ADRA1A—liver—type 2 diabetes mellitus	0.000201	0.0237	CbGeAlD
Naphazoline—Asthenia—Ramipril—type 2 diabetes mellitus	0.000201	0.00202	CcSEcCtD
Naphazoline—Nausea—Losartan—type 2 diabetes mellitus	0.000194	0.00195	CcSEcCtD
Naphazoline—ADRA2C—liver—type 2 diabetes mellitus	0.000192	0.0226	CbGeAlD
Naphazoline—Dizziness—Ramipril—type 2 diabetes mellitus	0.000185	0.00186	CcSEcCtD
Naphazoline—Headache—Ramipril—type 2 diabetes mellitus	0.000176	0.00176	CcSEcCtD
Naphazoline—Nausea—Ramipril—type 2 diabetes mellitus	0.000167	0.00167	CcSEcCtD
Naphazoline—Propranolol—CYP1A2—type 2 diabetes mellitus	0.000158	0.0349	CrCbGaD
Naphazoline—Propranolol—CYP3A4—type 2 diabetes mellitus	0.000105	0.0231	CrCbGaD
Naphazoline—ADRA1A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.16e-05	0.000138	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—GPX1—type 2 diabetes mellitus	1.16e-05	0.000138	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.16e-05	0.000137	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.15e-05	0.000137	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AVP—type 2 diabetes mellitus	1.15e-05	0.000137	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.15e-05	0.000137	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.15e-05	0.000137	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.15e-05	0.000136	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.14e-05	0.000136	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.13e-05	0.000134	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—CD36—type 2 diabetes mellitus	1.13e-05	0.000134	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.13e-05	0.000134	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.13e-05	0.000134	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.13e-05	0.000134	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.12e-05	0.000133	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PPP2CA—type 2 diabetes mellitus	1.12e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APOB—type 2 diabetes mellitus	1.12e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.11e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.11e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.11e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.11e-05	0.000132	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—SRC—type 2 diabetes mellitus	1.11e-05	0.000131	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.1e-05	0.000131	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.1e-05	0.00013	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.09e-05	0.00013	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.09e-05	0.000129	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.09e-05	0.000129	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.08e-05	0.000128	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—VEGFA—type 2 diabetes mellitus	1.08e-05	0.000128	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AVP—type 2 diabetes mellitus	1.08e-05	0.000128	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.08e-05	0.000128	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.07e-05	0.000127	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—MTHFR—type 2 diabetes mellitus	1.07e-05	0.000127	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.07e-05	0.000127	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—LPL—type 2 diabetes mellitus	1.07e-05	0.000126	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPARGC1A—type 2 diabetes mellitus	1.06e-05	0.000126	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—GNB3—type 2 diabetes mellitus	1.06e-05	0.000126	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.06e-05	0.000126	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—HMOX1—type 2 diabetes mellitus	1.06e-05	0.000125	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PPARA—type 2 diabetes mellitus	1.05e-05	0.000125	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.05e-05	0.000124	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—ADCY5—type 2 diabetes mellitus	1.04e-05	0.000124	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.04e-05	0.000124	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CAT—type 2 diabetes mellitus	1.04e-05	0.000124	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APOB—type 2 diabetes mellitus	1.04e-05	0.000124	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IGF1R—type 2 diabetes mellitus	1.04e-05	0.000123	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.04e-05	0.000123	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.03e-05	0.000122	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.03e-05	0.000122	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—EDN1—type 2 diabetes mellitus	1.03e-05	0.000122	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.02e-05	0.000121	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.02e-05	0.000121	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—AGT—type 2 diabetes mellitus	1.02e-05	0.000121	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.01e-05	0.00012	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—APOB—type 2 diabetes mellitus	1.01e-05	0.00012	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.01e-05	0.00012	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—CALM1—type 2 diabetes mellitus	1e-05	0.000119	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.99e-06	0.000119	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—APOE—type 2 diabetes mellitus	9.97e-06	0.000118	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—LPL—type 2 diabetes mellitus	9.95e-06	0.000118	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—TGFB1—type 2 diabetes mellitus	9.9e-06	0.000117	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—APOA1—type 2 diabetes mellitus	9.86e-06	0.000117	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—GSTM1—type 2 diabetes mellitus	9.85e-06	0.000117	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.81e-06	0.000116	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.74e-06	0.000116	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—LPL—type 2 diabetes mellitus	9.67e-06	0.000115	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.64e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.64e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—C3—type 2 diabetes mellitus	9.59e-06	0.000114	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.55e-06	0.000113	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.47e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—ADCY5—type 2 diabetes mellitus	9.46e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.46e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—GPX1—type 2 diabetes mellitus	9.43e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.42e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AVP—type 2 diabetes mellitus	9.42e-06	0.000112	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.38e-06	0.000111	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	9.34e-06	0.000111	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	9.34e-06	0.000111	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	9.25e-06	0.00011	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CD36—type 2 diabetes mellitus	9.18e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCR5—type 2 diabetes mellitus	9.17e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—HIF1A—type 2 diabetes mellitus	9.15e-06	0.000109	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IRS2—type 2 diabetes mellitus	9.12e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AGT—type 2 diabetes mellitus	9.11e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOB—type 2 diabetes mellitus	9.11e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.07e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2B—Hemostasis—AKT1—type 2 diabetes mellitus	9.07e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPP2CA—type 2 diabetes mellitus	9.07e-06	0.000108	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.96e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.96e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	8.96e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—C3—type 2 diabetes mellitus	8.96e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APOE—type 2 diabetes mellitus	8.93e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—LEP—type 2 diabetes mellitus	8.93e-06	0.000106	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—GNB3—type 2 diabetes mellitus	8.88e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.83e-06	0.000105	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AVP—type 2 diabetes mellitus	8.76e-06	0.000104	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MMP3—type 2 diabetes mellitus	8.76e-06	0.000104	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IGF2—type 2 diabetes mellitus	8.72e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—MTHFR—type 2 diabetes mellitus	8.7e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.7e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PPARG—type 2 diabetes mellitus	8.69e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.68e-06	0.000103	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.59e-06	0.000102	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.54e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPARA—type 2 diabetes mellitus	8.54e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.52e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—INS—type 2 diabetes mellitus	8.52e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.52e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AGT—type 2 diabetes mellitus	8.51e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2C—Hemostasis—AKT1—type 2 diabetes mellitus	8.47e-06	0.000101	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOB—type 2 diabetes mellitus	8.46e-06	0.0001	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.43e-06	0.0001	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PRKCB—type 2 diabetes mellitus	8.42e-06	9.99e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CALM1—type 2 diabetes mellitus	8.37e-06	9.93e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—LEP—type 2 diabetes mellitus	8.34e-06	9.9e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APOE—type 2 diabetes mellitus	8.34e-06	9.9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.33e-06	9.88e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AGT—type 2 diabetes mellitus	8.27e-06	9.81e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—APOA1—type 2 diabetes mellitus	8.24e-06	9.78e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.16e-06	9.68e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—CALM1—type 2 diabetes mellitus	8.13e-06	9.65e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—APOE—type 2 diabetes mellitus	8.1e-06	9.61e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—LPL—type 2 diabetes mellitus	8.08e-06	9.59e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.01e-06	9.51e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—APOA1—type 2 diabetes mellitus	8.01e-06	9.5e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.96e-06	9.45e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	7.91e-06	9.39e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.87e-06	9.33e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—C3—type 2 diabetes mellitus	7.83e-06	9.29e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—ALB—type 2 diabetes mellitus	7.81e-06	9.27e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—INS—type 2 diabetes mellitus	7.63e-06	9.05e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.58e-06	9e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.5e-06	8.91e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PIK3R1—type 2 diabetes mellitus	7.47e-06	8.87e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—NOS3—type 2 diabetes mellitus	7.47e-06	8.87e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.47e-06	8.86e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.45e-06	8.84e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.45e-06	8.84e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AGT—type 2 diabetes mellitus	7.44e-06	8.83e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.44e-06	8.83e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IGF1—type 2 diabetes mellitus	7.38e-06	8.76e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT2—type 2 diabetes mellitus	7.37e-06	8.75e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—EGFR—type 2 diabetes mellitus	7.34e-06	8.71e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.32e-06	8.68e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.29e-06	8.65e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.29e-06	8.65e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—C3—type 2 diabetes mellitus	7.28e-06	8.63e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.21e-06	8.55e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—INS—type 2 diabetes mellitus	7.12e-06	8.45e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PPARG—type 2 diabetes mellitus	7.06e-06	8.37e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CCL2—type 2 diabetes mellitus	7.01e-06	8.32e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	7.01e-06	8.31e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	6.94e-06	8.23e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IRS2—type 2 diabetes mellitus	6.92e-06	8.21e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—INS—type 2 diabetes mellitus	6.92e-06	8.21e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AGT—type 2 diabetes mellitus	6.91e-06	8.2e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.89e-06	8.18e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.89e-06	8.17e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Hemostasis—AKT1—type 2 diabetes mellitus	6.88e-06	8.17e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.88e-06	8.16e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.86e-06	8.14e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—PTGS2—type 2 diabetes mellitus	6.83e-06	8.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CALM1—type 2 diabetes mellitus	6.8e-06	8.07e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—LEP—type 2 diabetes mellitus	6.77e-06	8.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOE—type 2 diabetes mellitus	6.77e-06	8.04e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.7e-06	7.95e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.69e-06	7.94e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.69e-06	7.94e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.54e-06	7.77e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.5e-06	7.72e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.39e-06	7.58e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—ALB—type 2 diabetes mellitus	6.35e-06	7.53e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—RELA—type 2 diabetes mellitus	6.3e-06	7.47e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NOS3—type 2 diabetes mellitus	6.25e-06	7.41e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	6.25e-06	7.41e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—INS—type 2 diabetes mellitus	6.23e-06	7.39e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.13e-06	7.27e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PIK3R1—type 2 diabetes mellitus	6.07e-06	7.2e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—NOS3—type 2 diabetes mellitus	6.07e-06	7.2e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.04e-06	7.17e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.02e-06	7.15e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.02e-06	7.14e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.99e-06	7.11e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—RELA—type 2 diabetes mellitus	5.88e-06	6.98e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—INS—type 2 diabetes mellitus	5.79e-06	6.87e-05	CbGpPWpGaD
Naphazoline—ADRA2B—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.73e-06	6.8e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.72e-06	6.79e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.69e-06	6.76e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.68e-06	6.74e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.64e-06	6.7e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.6e-06	6.64e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.59e-06	6.64e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.57e-06	6.61e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—PTGS2—type 2 diabetes mellitus	5.55e-06	6.59e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.46e-06	6.48e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.46e-06	6.48e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.37e-06	6.37e-05	CbGpPWpGaD
Naphazoline—ADRA2C—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.35e-06	6.35e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.32e-06	6.31e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.31e-06	6.3e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.3e-06	6.29e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.27e-06	6.25e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.2e-06	6.18e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.14e-06	6.1e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.08e-06	6.02e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.08e-06	6.02e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.01e-06	5.95e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.96e-06	5.89e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—SRC—type 2 diabetes mellitus	4.95e-06	5.87e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.86e-06	5.77e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.82e-06	5.72e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—RELA—type 2 diabetes mellitus	4.78e-06	5.67e-05	CbGpPWpGaD
Naphazoline—ADRA1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.68e-06	5.55e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.64e-06	5.5e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—SRC—type 2 diabetes mellitus	4.62e-06	5.48e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.61e-06	5.47e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.5e-06	5.34e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.42e-06	5.25e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.38e-06	5.2e-05	CbGpPWpGaD
Naphazoline—ADRA2A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.35e-06	5.16e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.34e-06	5.15e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.34e-06	5.15e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.31e-06	5.11e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.28e-06	5.08e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.25e-06	5.04e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.13e-06	4.9e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.07e-06	4.83e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.05e-06	4.81e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.04e-06	4.79e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.03e-06	4.78e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	3.95e-06	4.69e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.94e-06	4.67e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—SRC—type 2 diabetes mellitus	3.75e-06	4.45e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.66e-06	4.34e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.61e-06	4.29e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.54e-06	4.2e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Metabolism—AKT1—type 2 diabetes mellitus	3.43e-06	4.08e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.36e-06	3.98e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—IL6—type 2 diabetes mellitus	3.33e-06	3.96e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.29e-06	3.9e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—IL6—type 2 diabetes mellitus	3.11e-06	3.69e-05	CbGpPWpGaD
Naphazoline—ADRA2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.07e-06	3.65e-05	CbGpPWpGaD
Naphazoline—ADRA2C—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.87e-06	3.41e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Metabolism—AKT1—type 2 diabetes mellitus	2.79e-06	3.31e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.72e-06	3.23e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.53e-06	3e-05	CbGpPWpGaD
Naphazoline—ADRA1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.51e-06	2.98e-05	CbGpPWpGaD
Naphazoline—ADRA2A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.33e-06	2.77e-05	CbGpPWpGaD
